Recent Updates
Recently added Catalysts
SGMT

Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress 2021 (EASL)

Thursday, April 22, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress 2021 (EASL)

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

Full Press Release Details

Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress 2021 (EASL).
ShareAdd on Google
Tags: SGMT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 22, 2021

Biotech snapshot

Cash runway
$258M liquidity · $4M/mo burn
~69 mo
Minimal dilution risk
Lead asset
TVB-2640Phase 2
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease →

Catalyst track record

+110%
best trade around SGMT's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for SGMT.

See every catalyst's timing & PoA →